PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Families in Gene Neighborhoods
June 2015
Signaling: A Platform for Opposing Functions
May 2015
Nuclear Pore Complex: A Flexible Transporter
February 2015
Nuclear Pore Complex: Higher Resolution of Macromolecules
February 2015
Nuclear Pore Complex: Integrative Approach to Probe Nup133
February 2015
Piecing Together the Nuclear Pore Complex
February 2015
iTRAQing the Ubiquitinome
July 2014
CAAX Endoproteases
August 2013
The Immune System: A Strong Competitor
June 2013
The Immune System: Strand Swapping for T-Cell Inhibition
June 2013
PDZ Domains
April 2013
Protein Interaction Networks: Adding Structure to Protein Networks
April 2013
Protein Interaction Networks: Morph to Assemble
April 2013
Protein Interaction Networks: Reading Between the Lines
April 2013
Protein Interaction Networks: When the Sum Is Greater than the Parts
April 2013
Alpha-Catenin Connections
March 2013
Cytochrome Oxidase
November 2012
Bacterial Phosphotransferase System
October 2012
Solute Channels
September 2012
Budding ensemble
August 2012
The machines behind the spindle assembly checkpoint
June 2012
G Protein-Coupled Receptors
May 2012
Revealing the Nuclear Pore Complex
March 2012
Topping off the proteasome
March 2012
Anchoring's the way
February 2012
Reading out regioselectivity
December 2011
An effective and cooperative dimer
November 2011
PDZ domains: sometimes it takes two
November 2011
Raising a glass to GLIC
August 2011
A2A Adenosine Receptor
May 2011
A growing family
February 2011
FERM-ly bound
February 2011
CXCR4
January 2011
Guard cells pick up the SLAC
December 2010
Zinc Transporter ZntB
July 2010
Zinc Transporter ZntB
July 2010
Importance of extension for integrin
June 2010
Spot protein-protein interactions… fast
March 2010
Alg13 Subunit of N-Acetylglucosamine Transferase
February 2010
Urea transporter
February 2010
Two-component signaling
December 2009
ABA receptor...this time for real?
November 2009
Network coverage
November 2009
Get3 into the groove
October 2009
Guanine Nucleotide Exchange Factor Vav1 and Rho GTPase Rac1
October 2009
GPCR subunits: Separate but not equal
September 2009
Proofreading RNA
July 2009
Ribonuclease and Ribonuclease Inhibitor
April 2009
The elusive helicase
April 2009
Click for cancer-protein interactions
December 2008

Research Themes Protein-protein interactions

The Immune System: A Strong Competitor

SBKB [doi:10.1038/sbkb.2012.144]
Featured Article - June 2013
Short description: HLA-DO is an MHCII mimic that prevents the association of HLA-DM to MHCII.

HLA-DM (α, blue; β, cyan) in complex with DO (α, red; β, magenta). The three major DO–DM interfaces are highlighted with yellow ovals. 1

Major histocompatibility class II (MHCII) complexes present peptide antigens to T cells as part of a mechanism that allows immune surveillance of self and foreign antigens and activation of an immune response. Two MHCII-like proteins, HLA-DM and HLA-DO in humans, modulate peptide presentation in the endosomes of antigen-presenting cells. HLA-DM catalyzes the removal of a short peptide called CLIP, a remnant of the protein that escorts the MHCII complex from the endoplasmic reticulum to the endosome. Removal of CLIP allows binding of pathogen- and self-derived peptides to the MHCII binding groove. In addition, HLA-DM also promotes the dissociation of weakly bound peptides, ensuring the accumulation of high-affinity peptides. HLA-DO associates with HLA-DM and inhibits its peptide exchange properties, but the exact mechanism was previously unknown.

Using crystallography, mutagenesis and kinetic studies, Stern and colleagues show that HLA-DO is a substrate mimic that binds HLA-DM and inhibits its interaction with MHCII. The crystal structure of the HLA-DO–HLA-DM complex (PDB 4I0P) shows that HLA-DO has an overall topology very similar to classical MHCII molecules and binds HLA-DM in the same region as MHCII. Mutagenesis and peptide-binding kinetic analysis confirm that HLA-DO engages the same residues as MHCII, but binds with higher affinity.

These findings have important implications for how tolerance to self-antigens is maintained and for peptide repertoire modulation. In fact, HLA-DO-deficient mice have a different spectrum of MHCII-bound peptides than wild-type animals, and this is potentially related to differing cellular localization of HLA-DO and HLA-DM. In the multivesicular body, where MHCII complexes associate with peptides, HLA-DM is present in both the inner and outer membranes, while HLA-DO appears only in the latter. This suggests that MHCII molecules on the inner membrane are free to associate with HLA-DM and are consequently loaded with high-affinity peptides, while MHCII molecules on the outer membrane must scavenge for low-affinity peptides. Therefore, the presence of HLA-DO may promote the surface expression of self-peptides, which are of lower affinity than pathogen-derived peptides, and thus contribute to maintenance of tolerance to self.

Ioana Visan

References

  1. A.I. Guce et al. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.
    Nat. Struct. Mol. Biol. 20, 90-98 (2013). doi:10.1038/nsmb.2460

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health